BeiGene has officially launched its PD-1 cancer drug Tevimbra in the U.S. more than six months after receiving a much-delayed ...

PD-1 inhibitors have revolutionised cancer treatment over the last decade, with their success attributed to Keytruda and ...

Recent headlines about a potent new immunotherapy have mostly focused on the U.S. company helping to develop it. Less ...

ABL Bio (CEO Sang Hoon Lee), a company specializing in bispecific antibodies, today announced that it has entered into a ...

Keytruda continued to improve survival versus Yervoy in unresectable stage 3 or 4 melanoma in long-term follow-up data.

An attempt by Merck & Co. to unlock the microsatellite stable (MSS) metastatic colorectal cancer market has ended in failure.

Merck follows in the footsteps of Bristol Myers Squibb, which in December 2023 also failed to secure a late-stage victory for ...

Merck & Co.’s said a late-stage trial of its blockbuster cancer drug Keytruda in combination with favezelimab failed to meet ...

Merck & Co Inc (NYSE:MRK) released topline data from the KEYFORM-007 Phase 3 study of the fixed-dose combination of ...

A huge leap in fines for misusing mobility parks, help with childcare and access to new drugs are just some of the measures ...

In a triple whammy of good news, 1 October heralds the beginning of the funding of two major health products and a welcome contribution to early childhood fees, Prime Minister Christopher Luxon says.

Their success is attributed to two of the first PD-1 inhibitors to be approved, Keytruda (pembrolizumab) and Opdivo (nivolumab). Ten years on from their approval, GlobalData reviews their market ...